Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01877811
Recruitment Status : Completed
First Posted : June 14, 2013
Last Update Posted : April 25, 2019
Information provided by (Responsible Party):
Hoffmann-La Roche